$0
CARTITUDE-1 and CARTITUDE-2 Study Updates; Carvykti Improves Clinical Outcomes Compared to Real-World Clinical Practice in R/R MM; ASH 2021 Day 3 Legend Investor Event
On Monday, December 13, Legend held their investor event highlighting updated clinical results from Carvykti’s (BCMA CAR-T; cilta-cel) Ph1b/2 CARTITUDE-1 and Ph2 CARTITUDE-2 studies in r/r MM. Below, Celltelligence provides insights on Carvykti’s improved efficacy profile compared to real-world clinical practice (RWCP) in r/r MM, while discussing whether a GSI combination is necessary to improve a BCMA CAR-T’s efficacy.